转移性结直肠癌分子靶向治疗的研究进展  

Research Progress of Molecular Target Therapy for Metastatic Colorectal Cancer

作　　者：梁慧玲[1] 何晓琴[1] 甘园园[1] 周宇杰[1] 熊琳 陈心[1] 唐甜[1] 徐细明[1] LIANG Huiling;HE Xiaoqin;GAN Yuanyuan;ZHOU Yujie;XIONG Lin;CHEN Xin;TANG Tian;XU Ximing(Cancer Center,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院肿瘤中心,武汉430060

出　　处：《医学综述》2018年第5期873-878,共6页Medical Recapitulate

基　　金：国家自然科学基金(81402242)

摘　　要：结直肠癌是常见的消化道肿瘤,且大部分为转移性结直肠癌(mCRC)。而化疗联合靶向药物治疗mCRC可明显获益。目前,已在临床应用或正在研究的针对mCRC靶向治疗的药物包括抑制血管生成的靶向治疗药物、表皮生长因子受体靶向治疗药物和免疫靶向治疗药物等。其中,表皮生长因子受体靶向治疗药物适用于基因检测结果为大鼠肉瘤病毒癌基因同源物野生型的mCRC患者,但结直肠癌的左右侧分型、鼠类肉瘤滤过性病毒致癌同源体B1突变和人类表皮生长因子受体2扩增情况均影响其治疗效果。免疫靶向治疗药物建议用于高度微卫星不稳定表型的mCRC患者。而抑制血管生成的靶向药物目前仍缺乏可靠的生物标志物进行疗效预测,故未来需进一步研究。Colorectal cancer is a common digestive tract tumor,most of which is metastatic colorectal cancer(mCRC).However,the combination of chemotherapy and targeted drug therapy can benefit mCRC significantly.At present,targeted therapies for mCRC about clinical applications or ongoing research include:therapies targeting angiogenesis,epidermal growth factor receptor targeted therapy and immunotherapy.Among them,the epithelial growth factor receptor therapy is used for the patients with mCRC of sarcoma viral oncogene homolog wild type,but for patients with different tumor sidedness,mutation in V-raf murine sarcoma viral oncogene homolog B1 mutations and amplifications in human epidermal growth factor receptor 2,the therapeutic effect is diverse.Immune targeted drugs are recommended to the mCRC patients with high microsatellite instability phenotypes.The targeted drugs that inhibit angiogenesis still lack a reliable biomarker to predict the curative effect,so further study is needed in the future.

关 键 词：转移性结直肠癌 分子靶向治疗 血管内皮生长因子 表皮生长因子受体 

分 类 号：R735.35[医药卫生—肿瘤]